Clinical Trials Logo

Malignant Neoplasm of Breast clinical trials

View clinical trials related to Malignant Neoplasm of Breast.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05033756 Recruiting - Breast Cancer Clinical Trials

Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO

COMPRENDO
Start date: July 30, 2022
Phase: Phase 2
Study type: Interventional

This study will examine the combination of pembrolizumab and olaparib in three populations. - Cohort 1: aBC patients with a germline mutation in BRCA1 or BRCA2, - cohort 2: aBC patients with a germline mutation in one of the moderate penetrance homologous repair genes (ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2), and - cohort 3: aBC patients with a HRD as assessed by whole genome sequencing.

NCT ID: NCT04669873 Recruiting - Clinical trials for Malignant Neoplasm of Breast

Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery

LAPIDARY
Start date: March 4, 2021
Phase: N/A
Study type: Interventional

Radiotherapy has been confirmed as an important treatment breast-conserving surgery reducing the risk of any recurrence of breast cancer and breast cancer-related mortality in patients with early breast cancer. There are no comparative data on the ideal radiotherapy treatment regimen for patients with early stage breast cancer who underwent conservative surgery in the Brazilian population.

NCT ID: NCT04654208 Recruiting - Clinical trials for Malignant Neoplasm of Breast

Swedish Ibrance Registries Insights (SIRI)

SIRI
Start date: December 15, 2020
Phase:
Study type: Observational

The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.

NCT ID: NCT03463954 Recruiting - Clinical trials for Malignant Neoplasm of Breast

Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors

Start date: August 9, 2023
Phase: N/A
Study type: Interventional

Prior to this confirmatory pivotal study, the multicenter Br-002 feasibility study was completed. 98% of tumors less than or equal to 15mm were completely ablated in one procedure.This study will evaluate Novilase for the focal destruction of malignant tumors of the breast that are less than or equal to 15 mm against a performance goal for the standard of care, lumpectomy. The ASBrS' goal of less than 20% retreatment by 2020 was selected as a representative performance goal, i.e., 80.0%, and is consistent with published effectiveness rates for lumpectomy.